169 related articles for article (PubMed ID: 35560823)
1. Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor.
Li X; Shelton MJ; Wang J; Meade J; Ruiz-Soto R
Clin Pharmacol Drug Dev; 2022 Oct; 11(10):1165-1176. PubMed ID: 35560823
[TBL] [Abstract][Full Text] [Related]
2. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
Li J; Rockich K; Yuska B; Zhou G; Epstein N; Punwani N; Chen X; Yeleswaram S
J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
[TBL] [Abstract][Full Text] [Related]
3. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
Mu S; Lin C; Skrzypczyk-Ostaszewicz A; Bulat I; Maglakelidze M; Skarbova V; Andreu-Vieyra C; Sahasranaman S
Cancer Chemother Pharmacol; 2021 Jul; 88(1):81-88. PubMed ID: 33772633
[TBL] [Abstract][Full Text] [Related]
5. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
[TBL] [Abstract][Full Text] [Related]
7. Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers.
Zhang S; Jin S; Griffin C; Feng Z; Lin J; Venkatakrishnan K; Gupta N
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1044-1053. PubMed ID: 34145979
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J
Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634
[TBL] [Abstract][Full Text] [Related]
9. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.
Mu S; Tang Z; Novotny W; Tawashi M; Li TK; Ou Y; Sahasranaman S
Cancer Chemother Pharmacol; 2020 Feb; 85(2):391-399. PubMed ID: 31875923
[TBL] [Abstract][Full Text] [Related]
10. Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects.
Barbour AM; Punwani N; Epstein N; Landman R; Cimino E; Yuska B; Wang P; He K; Chen X; Yeleswaram S
J Clin Pharmacol; 2019 Dec; 59(12):1641-1647. PubMed ID: 31282592
[TBL] [Abstract][Full Text] [Related]
11. Effects of Strong Inhibition of Cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and Strong Induction of Cytochrome P450 3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two Drug-Drug Interaction Studies in Healthy Volunteers.
Yin W; Dong C; Stevenson A; Lloyd V; Petrillo M; Baratta M; Hui T; Han S
Drug Metab Dispos; 2024 Feb; 52(3):180-187. PubMed ID: 38123352
[TBL] [Abstract][Full Text] [Related]
12. Effect of CYP3A4 induction and inhibition on the pharmacokinetics of SHR0302 in healthy subjects.
Zhang Z; Gao X; Zhang P; Li Y; Fu M; Lin H; Feng S; Shen K; Yu G; Li X
Br J Clin Pharmacol; 2023 Aug; 89(8):2561-2568. PubMed ID: 37005376
[TBL] [Abstract][Full Text] [Related]
13. Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.
Ogasawara K; MacGorman K; Liu L; Chen J; Carayannopoulos LN; Zhou S; Palmisano M; Li Y
J Clin Pharmacol; 2019 Dec; 59(12):1620-1631. PubMed ID: 31172535
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole.
Liu X; Zhang Y; Chen Q; Zhan Y; Wang Q; Hu C; Yu C; Guo Z; Chen X; Zhong D
J Clin Pharmacol; 2018 Mar; 58(3):347-356. PubMed ID: 28967981
[TBL] [Abstract][Full Text] [Related]
15. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Wrishko RE; McCrea JB; Yee KL; Liu W; Panebianco D; Mangin E; Chakravarthy M; Martinez-Cantarin MP; Kraft WK
Clin Drug Investig; 2019 May; 39(5):441-451. PubMed ID: 30810914
[TBL] [Abstract][Full Text] [Related]
16. Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.
Zhou X; Pant S; Nemunaitis J; Craig Lockhart A; Falchook G; Bauer TM; Patel M; Sarantopoulos J; Bargfrede M; Muehler A; Rangachari L; Zhang B; Venkatakrishnan K
Invest New Drugs; 2018 Apr; 36(2):248-258. PubMed ID: 28852909
[TBL] [Abstract][Full Text] [Related]
17. The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
Elgart A; Greenblatt DJ; Loupe PS; Zur AA; Weiss S; Mimrod D; Spiegelstein O
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1015-1024. PubMed ID: 32237115
[TBL] [Abstract][Full Text] [Related]
18. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
Vishwanathan K; Dickinson PA; So K; Thomas K; Chen YM; De Castro Carpeño J; Dingemans AC; Kim HR; Kim JH; Krebs MG; Chih-Hsin Yang J; Bui K; Weilert D; Harvey RD
Br J Clin Pharmacol; 2018 Jun; 84(6):1156-1169. PubMed ID: 29381826
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of drug-drug interactions of pemigatinib in healthy participants.
Ji T; Rockich K; Epstein N; Overholt H; Wang P; Chen X; Punwani N; Yeleswaram S
Eur J Clin Pharmacol; 2021 Dec; 77(12):1887-1897. PubMed ID: 34282472
[TBL] [Abstract][Full Text] [Related]
20. A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors.
Schueller O; Willson A; Singh N; Lohmer L; Alabanza A; Patel J
Clin Pharmacol Drug Dev; 2022 Jul; 11(7):795-806. PubMed ID: 35230741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
